Zhitong Finance App News, Colon Pharmaceutical (002422.SZ) issued an announcement. The company recently learned that the new drug clinical trial (IND) application for the targeted integrin beta-6 (ITGB6) antibody conjugate drug (ADC) SKB105 (also known as CR-003) independently developed by the company's holding subsidiary, Sichuan Colun Botai Biomedical Co., Ltd. (hereinafter referred to as “Columbotai”), has been approved by the China National Drug Administration (NMPA) Drug Evaluation Center (CDE) for the treatment of advanced solid tumors.

Zhitong Finance App News, Colon Pharmaceutical (002422.SZ) issued an announcement. The company recently learned that the new drug clinical trial (IND) application for the targeted integrin beta-6 (ITGB6) antibody conjugate drug (ADC) SKB105 (also known as CR-003) independently developed by the company's holding subsidiary, Sichuan Colun Botai Biomedical Co., Ltd. (hereinafter referred to as “Columbotai”), has been approved by the China National Drug Administration (NMPA) Drug Evaluation Center (CDE) for the treatment of advanced solid tumors.